Beta Bionics announced a pivotal bihormonal iLet home trial\u00a0using both dasiglucagon and insulin in the\u00a0aforementioned bionic pancreas. The\u00a0iLet (dual-hormone pump system) designed to autonomously deliver insulin and dasiglucagon. The bionic pancreas offers people with type 1 diabetes, safer and easier blood sugar control. Therefore, better long-term management and outcomes are possible as well.\r\nWhat is Dasiglucagon\r\nAccording to Zealand Pharma, dasiglucagon is an analog of human glucagon which is stable in\u00a0aqueous formulation. Therefore, used for the treatment of type 1 diabetes in a dual-hormone artificial pancreas pump containing insulin and glucagon. Glucagon works to raise the concentration of glucose and fatty acids in the bloodstream.\r\n\r\nRead the full press release on the bihormonal iLet home trial by Beta Bionics here!